GemPharmatech Co., Ltd. (SHA:688046)
China flag China · Delayed Price · Currency is CNY
31.39
-3.11 (-9.01%)
Nov 16, 2026, 4:00 PM EST

GemPharmatech Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
385.16486.62701.37560.17421.71293.52
Short-Term Investments
-23.06-120.1--
Trading Asset Securities
715.75757.69467.34637.72791.24205.8
Cash & Short-Term Investments
1,1011,2671,1691,3181,213499.31
Cash Growth
-8.14%8.44%-11.33%8.66%142.92%-4.75%
Accounts Receivable
424.8384.96350.81269.39185.45118.57
Other Receivables
4.584.246.286.093.6339.68
Receivables
429.38389.2357.09275.48189.08158.25
Inventory
104.0572.9654.247.0949.4730.08
Prepaid Expenses
-----3.41
Other Current Assets
159.9121.94129.7816.9615.5115.87
Total Current Assets
1,7941,7511,7101,6581,467706.93
Property, Plant & Equipment
678.17693.72626.28624.9375.15232.78
Long-Term Investments
107.11282.23109.05175.53306.9430.08
Other Intangible Assets
66.9971.3749.0547.3448.5149.53
Long-Term Deferred Tax Assets
33.4733.1435.9831.8517.054.81
Long-Term Deferred Charges
24.3928.4840.5836.6819.2924.63
Other Long-Term Assets
201.554.651.943.7719.775.66
Total Assets
2,9062,8652,5732,5782,2541,054

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
75.6568.1372.18101.8650.7961.73
Accrued Expenses
45.7361.2457.4250.9446.5639.04
Short-Term Debt
116.22187.3388.0476.1612.215.15
Current Portion of Leases
25.723.758.829.42.61-
Current Income Taxes Payable
16.427.072.8414.894.096.44
Current Unearned Revenue
184.45176.4138.23108.4289.1575.91
Other Current Liabilities
14.173.223.684.758.663.47
Total Current Liabilities
478.33527.14371.2366.41214.07191.74
Long-Term Debt
-----20.03
Long-Term Leases
66.780.2335.6236.073.050.02
Long-Term Unearned Revenue
24.8622.5622.941.0448.9950.49
Long-Term Deferred Tax Liabilities
7.767.938.29.419.96.5
Total Liabilities
577.65637.87437.92452.93276268.78

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
410.19410410410410360
Additional Paid-In Capital
1,2631,2531,2611,2581,254276.73
Retained Earnings
665.37572.95487.61455.4313.3148.63
Treasury Stock
-16.02-16.02-32.67---
Comprehensive Income & Other
5.847.078.641.090.910.27
Total Common Equity
2,3282,2272,1352,1251,978785.63
Shareholders' Equity
2,3282,2272,1352,1251,978785.63
Total Liabilities & Equity
2,9062,8652,5732,5782,2541,054

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
208.61291.31132.48121.6217.8625.2
Net Cash (Debt)
892.3976.061,0361,1961,195474.11
Net Cash Growth
2.44%-5.81%-13.39%0.11%152.07%-8.68%
Net Cash Per Share
2.202.402.552.943.051.33
Filing Date Shares Outstanding
409.16408.97407.41410410410
Total Common Shares Outstanding
409.16408.97407.41410410360
Working Capital
1,3161,2241,3391,2911,253515.19
Book Value Per Share
5.695.455.245.184.822.18
Tangible Book Value
2,2612,1562,0862,0771,929736.1
Tangible Book Value Per Share
5.535.275.125.074.712.04
Buildings
-430.58324.85311.6797.0897.78
Machinery
-278.89263.75229.67129.293.79
Construction In Progress
-22.4690.8589.6171.6753.02